Oral Treatment and prophylaxis of postmenopausal or corticosteroid-induced osteoporosis
Adult: 5 mg daily. Alternatively, for postmenopausal osteoporosis, 35 mg once wkly, or 75 mg on 2 consecutive days of each mth, or 150 mg once mthly.
Oral Paget's disease of bone
Adult: 30 mg once daily for 2 mth, may repeat if necessary after 2 mth interval.
Oral Increase bone mass in men with osteoporosis
Adult: 35 mg once wkly.
Hypocalcaemia, abnormalities of the oesophagus which may delay emptying (e.g. stricture or achalasia), inability to stand or sit upright for at least 30 min. Severe renal impairment (CrCl <30 mL/min). Lactation.
Correct hypocalcaemia and evaluate sex steroid hormonal status prior to therapy. Mild to moderate renal impairment. Pregnancy.
Arthralgia, back pain, GI disturbances (e.g. abdominal pain, dyspepsia), hypersensitivity reactions (e.g. angioedema, rash, bullous skin reactions), Stevens-Johnson syndrome, toxic epidermal necrolysis, leukocytoclastic vasculitis, alopecia, hepatic disorders, eye disorders (e.g. iritis, uveitis), osteonecrosis of the jaw, atypical femur fractures; bone, joint or muscle pain.
Monitor serum Ca; biochemical markers of bone turnover; bone mineral density (osteoporosis); alkaline phosphatase (Paget's disease).
Symptoms: Hypocalcaemia, hypophosphatemia. Management: Admin milk or antacids to reduce absorption. Gastric lavage may be considered in cases of substantial overdose. May give IV Ca to relieve signs and symptoms of hypocalcaemia.
Decreased absorption w/ antacids or mineral supplements containing divalent cations (e.g. Al, Ca, Mg).
Food reduces absorption.
May interfere w/ diagnostic imaging agents (e.g. technetium-99m-diphosphonate) in bone scans.
Description: Risedronic acid inhibits bone resorption via actions on osteoclast or on osteoclast precursors. It reduces bone turnover while the osteoblast activity and bone mineralisation is preserved. Pharmacokinetics: Absorption: Poorly absorbed from the GI tract. Decreased bioavailability when administered w/ food. Bioavailability: 0.63%. Time to peak plasma concentration: Approx 1 hr. Distribution: Volume of distribution: 6.3 L/kg. Plasma protein binding: Approx 24%. Metabolism: Not metabolised. Excretion: Via urine (about half of absorbed amount); faeces (unabsorbed drug). Terminal half-life: 480 hr.
M05BA07 - risedronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Anon. Risedronate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/09/2015.Buckingham R (ed). Risedronate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/09/2015.McEvoy GK, Snow EK, Miller J et al (eds). Risedronate Sodium. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 04/09/2015.Risedronate Sodium Hemi-Pentahydrate and Risedronate Sodium Monohydrate Tablet, Film-Coated (Actavis Pharma, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/09/2015.